// App-Quantinova.ai

608 : Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)

Researchers

Presenter

  • Georgina Long AO

Principal Investigators

  • Abraham Apfel

  • David Paulucci

  • Scott Chasalow

  • Daniel Tenney

  • Gina Fusaro

  • Dirk Schadendorf

  • Hussein Tawbi

  • F Stephen Hodi

  • Pratik Thakkar

  • James Larkin

  • Jedd Wolchok

  • Megan Wind-Rotolo

  • Shu-Pang Huang

  • Peter Mohr

  • Caroline Robert

  • Christoph Hoeller

  • Jean-Jacque Grob

  • Helen Gogas

  • Jeffrey Weber

  • Han Chang

  • Rebecca Moss

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Aix Marseille University, Marseille, France

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TX.

  • Medical University of Vienna, Vienna, Austria

  • University Hospital of Essen, Essen, Germany

  • National and Kapodistrian University of Athens, Athens, Greece

  • Memorial Sloan Kettering Cancer Center; Weill Cornell Medicine; Parker Institute for Cancer Immunotherapy, New York, NY, United States

  • Royal Marsden Hospital, London,

  • NYU Langone New York NY United States

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Elbe-Klinikum Buxtehude, Buxtehude, Germany

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • United States

  • Greece

  • France

  • Australia

  • Germany

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved